A comprehensive appraisal of dabigatran etexilate clinical evidence and applications : a 10-year-long story
Articolo
Data di Pubblicazione:
2021
Citazione:
A comprehensive appraisal of dabigatran etexilate clinical evidence and applications : a 10-year-long story / G.F. Romiti, B. Corica, M. Proietti. - In: FUTURE CARDIOLOGY. - ISSN 1479-6678. - 17:2(2021), pp. 215-226. [10.2217/fca-2020-0084]
Abstract:
During the last decade, non-vitamin K antagonist oral anticoagulants (NOACs) revolutionized the thromboprophylaxis management of several medical conditions, including atrial fibrillation and venous thromboembolism. Dabigatran etexilate was the first NOAC widely available worldwide, and it is currently the only one that directly inhibits thrombin. More recently, the availability of idarucizumab, a specific reversal agent, has increased the safety of dabigatran use in clinical practice, especially for those patients with severe and life-threatening bleeding. This review aims to summarize current evidence on dabigatran, starting from its pharmacological characteristics, and providing an updated overview of pivotal randomized controlled trials and real-world data on its efficacy and safety.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
atrial fibrillation; dabigatran; non-vitamin K antagonist oral anticoagulants; oral anticoagulant drugs; thromboembolic risk
Elenco autori:
G.F. Romiti, B. Corica, M. Proietti
Link alla scheda completa: